UroAlert - GU Oncology Daily

June 24, 2026

Videos

Peer-to-Peer Clinical Conversations

PSA Response as a Guide in Metastatic Hormone-Sensitive Prostate Cancer Treatment - Tanya Dorff

Tanya Dorff

Tanya Dorff discusses PSA monitoring and treatment decisions in metastatic hormone-sensitive prostate cancer.

Expanding Bladder Cancer Trials and Multidisciplinary Membership in the SUO-CTC - Trinity Bivalacqua

Trinity Bivalacqua

Trinity Bivalacqua discusses SUO-CTC updates with Ashish Kamat.

Beyond the Abstracts

Peritoneal Recurrence Following Nephrectomy for Localized Renal Cancer: A Multicenter European Real-World Analysis of Incidence, Pattern and Treatment (PEMET Study-UroCCR 124) - Beyond the Abstract

The Influence of Immunocompromised Status on Recurrence and Progression Free Survival Among Nonmuscle Invasive Bladder Cancers (NMIBCs) Undergoing Transurethral Resection of Bladder Tumor (TURBT) - Beyond the Abstract

Conference Coverage

ASCO 2026: LITESPARK-033: Phase 3 Study of Belzutifan + Zanzalintinib Versus Cabozantinib for Recurrent Clear Cell RCC During or After Adjuvant Anti-PD-(L)1 Therapy

ASCO 2026: Discussant - PARPi-Palooza: Sorting out the Many Options in Prostate Cancer

ASCO 2026: Discussant - Nectin-4 Antibody-Drug Conjugates: The Past, Present, and Future

AUA 2026: Delayed Survival Benefit of Enzalutamide Plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer: A Reconstructed Individual Patient Data Analysis of the PEACE-3 Trial

AUA 2026: Safety of Rucaparib versus Docetaxel or Second-generation Androgen Receptor Pathway Inhibitor Therapy for Patients with Metastatic Castration-resistant Prostate Cancer and a BRCA mutation in TRITON3

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Phase 2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guérin (BCG)‒Naïve Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3-Year Outcomes.

CRISPR/Cas9-mediated miR-21 editing in high-grade urothelial carcinoma cells and its biological effects.

Renal Cancer

Imaging modality, incidental detection, and age-stage distribution in surgically treated clear cell renal cell carcinoma.

Targeting RELA and STAT3 regulates TNFRSF10A-mediated apoptosis in a novel apoptosis-based prognostic model for clear cell renal cell carcinoma.

Prostate Cancer

Outcome after primary directed radiotherapy in predominantly PSMA-PET/CT-staged patients with metastatic prostate cancer.

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Testosterone Therapy After Radical Prostatectomy: Insights From a Systematic Review and Meta-Analysis.

Clinically Significant Prostate Cancer in Patients Undergoing Holmium Laser Enucleation of Prostate for Benign Hyperplasia: A Preoperative Nomogram and a Postoperative Surveillance Protocol.

Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice.

Longitudinal Tumor Mutation Burden Dynamics in Advanced Prostate Cancer Using Circulating Tumor DNA Profiling.

Stockholm3-Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up.

Same Target, Different Tools: A Multicenter Comparison of Clinically Significant Prostate Cancer Detection Across Three MRI-Targeted Transperineal Biopsy Techniques

NeuroSAFE-Guided Robot-Assisted Radical Prostatectomy versus Standard RARP: Systematic Review and Meta-Analysis of Comparative Studies - Beyond the Abstract

Upper Tract Tumors

Nephroureterectomy with ileal cuff for upper tract recurrence after radical cystectomy: oncologic and survival outcomes.

Testicular Cancer

Parental occupational exposure to pesticides at birth and risk of adult testicular germ cell tumours in offspring: a French nationwide case-control study.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC